Concepts (50)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| T-Lymphocytes | 2 | 2024 | 46 | 0.990 |
Why?
|
| Neoplasms | 2 | 2023 | 90 | 0.880 |
Why?
|
| Peptides | 6 | 2024 | 49 | 0.860 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2024 | 8 | 0.850 |
Why?
|
| Molecular Dynamics Simulation | 2 | 2024 | 32 | 0.410 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2024 | 5 | 0.410 |
Why?
|
| Proteins | 2 | 2023 | 46 | 0.240 |
Why?
|
| Humans | 8 | 2024 | 4936 | 0.230 |
Why?
|
| Citrullination | 1 | 2024 | 1 | 0.220 |
Why?
|
| HLA-DRB1 Chains | 1 | 2024 | 1 | 0.220 |
Why?
|
| Vimentin | 1 | 2024 | 5 | 0.220 |
Why?
|
| Alleles | 1 | 2024 | 16 | 0.220 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2024 | 12 | 0.220 |
Why?
|
| Hominidae | 1 | 2024 | 1 | 0.210 |
Why?
|
| Interferon-gamma | 1 | 2024 | 7 | 0.210 |
Why?
|
| Sulfonamides | 1 | 2024 | 8 | 0.210 |
Why?
|
| Connectin | 1 | 2023 | 1 | 0.200 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2023 | 4 | 0.200 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2023 | 8 | 0.200 |
Why?
|
| HLA-G Antigens | 1 | 2023 | 1 | 0.200 |
Why?
|
| DNA-Binding Proteins | 1 | 2023 | 22 | 0.190 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2022 | 1 | 0.190 |
Why?
|
| Protein Binding | 3 | 2024 | 115 | 0.150 |
Why?
|
| Epitopes | 2 | 2024 | 3 | 0.100 |
Why?
|
| Animals | 2 | 2024 | 1711 | 0.070 |
Why?
|
| Citrulline | 1 | 2024 | 1 | 0.060 |
Why?
|
| Major Histocompatibility Complex | 1 | 2024 | 1 | 0.050 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2024 | 11 | 0.050 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2024 | 10 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 27 | 0.050 |
Why?
|
| Prognosis | 1 | 2024 | 60 | 0.050 |
Why?
|
| Protein Conformation | 1 | 2023 | 43 | 0.050 |
Why?
|
| Clone Cells | 1 | 2023 | 4 | 0.050 |
Why?
|
| Placenta | 1 | 2023 | 4 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2023 | 20 | 0.050 |
Why?
|
| Leukocyte Immunoglobulin-like Receptor B1 | 1 | 2023 | 1 | 0.050 |
Why?
|
| Genes, MHC Class I | 1 | 2023 | 2 | 0.050 |
Why?
|
| Mammals | 1 | 2023 | 18 | 0.050 |
Why?
|
| Amino Acid Sequence | 1 | 2023 | 49 | 0.050 |
Why?
|
| Protein Isoforms | 1 | 2023 | 13 | 0.050 |
Why?
|
| Pregnancy | 1 | 2023 | 89 | 0.050 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2022 | 1 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2023 | 66 | 0.050 |
Why?
|
| HLA Antigens | 1 | 2022 | 1 | 0.050 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2022 | 1 | 0.050 |
Why?
|
| Systems Biology | 1 | 2022 | 3 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2022 | 37 | 0.050 |
Why?
|
| Computational Biology | 1 | 2022 | 32 | 0.050 |
Why?
|
| Phylogeny | 1 | 2022 | 59 | 0.040 |
Why?
|
| Female | 1 | 2023 | 2523 | 0.030 |
Why?
|